estosterone stimulates erythropoiesis, while testosterone replacement therapy increases hemoglobin concentration (1, 2) . One might suspect that declining serum testosterone concentrations during aging could compromise erythropoiesis. Accordingly, men with hypogonadism as well as those treated with antiandrogenic drugs frequently have anemia (3, 4) . Since the influence of serum bioavailable testosterone on hemoglobin concentration has not been investigated in men with type 2 diabetes, we presently examined this relationship and its possible implications for management of diabetes.
Measurements of glycated hemoglobin (HbA1c) and glycated albumin (GA) have been used clinically to monitor glycemic control in patients with diabetes mellitus. HbA1c represents an integrated measurement of blood glucose during the preceding 2 months while serum GA, a shorter-term marker, reflects glycemic control over approximately the preceding 2 weeks (5-7). GA is not influenced by a number of physiologic and pathologic conditions that affect HbA1c levels, such as anemia and genetic hemoglobin abnormalities (8, 9) .
The considerations above raise the possibility that HbA1c levels might be relatively low in male diabetic patients with hypogonadism. To our knowledge, relationships between serum endogenous androgens and the ratio of GA to HbA1c (GA/HbA1c) have not been explored in men with type 2 diabetes. We therefore investigated the effect of serum bioavailable testosterone concentration on GA/HbA1c in these patients. Intra-assay and interassay coefficients of variation (CV) for serum bioavailable testosterone concentrations at 1pg/mL were 4.73% and 12.94%, respectively. Hemoglobin concentrations were analyzed within 4 hr of blood drawing using a SYSMEX XE-2100 autoanalyzer (Sysmex Corporation, Kobe, Japan). HbA1c was measured by highperformance liquid chromatography using an ADAMS-A1c HA-8160 (Arkray, Kyoto, Japan). Interassay CV determined using representative blood samples with T 5.2% and 10.9% HbA1c was 0.63% and 0.45%, respectively. GA was determined by an enzymatic method using albuminspecific proteinase, ketoamine oxidase, and an albumin assay reagent (Lucica GA-L; Asahi Kasei Pharma, Tokyo, Japan), with a Hitachi 7600 autoanalyzer (Hitachi Instrument Service, Tokyo, Japan). Interassay CV determined using representative serum samples with 17.2% and 26.9% GA was 1.08% and 1.37%, respectively. Plasma total cholesterol, HDL cholesterol, and triglyceride concentrations were assessed using standard enzymatic methods. Mean values for biochemical parameters obtained during the preceding year were used for statistical analysis. Urinary albumin and creatinine concentration were determined in early morning spot urine. Urinary albumin excretion was measured with an immunoturbidimetric assay. A mean value for urinary albumin excretion was determined from three urine collections.
RESEARCH
Type 2 diabetes was diagnosed according to the Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (11) . Retinopathy was graded as no diabetic retinopathy (NDR), simple diabetic retinopathy (SDR), or proliferative diabetic retinopathy (PDR). Nephropathy was graded as normoalbuminuria, urinary albumin excretion <30 mg/g Cr; or microalbuminuria, 30-300 mg/g Cr. Sitting blood pressure was measured after a 5-min rest. CVD was defined as a previous myocardial or cerebral infarction based on the clinical history or physical examination. Subjects were classified as nonsmokers, past smokers, or current smokers according to a self-administered questionnaire. Patients were excluded if they had undergone castration for treatment of testicular or prostate cancer, or were taking any medications known to affect sex hormone concentrations (e.g., antiandrogenic agents for prostate cancer). In addition, patients with macroalbuminuria were excluded since advanced diabetic nephropathy can influence hemoglobin concentration. Moreover, patients with malignant disease, liver cirrhosis, thyroid disorders, hematologic disease, or infectious disease were excluded from this study. To minimize effects of diabetic treatment on time-dependent variations of HbA1c and GA levels, we selected patients whose HbA1c levels had been stable for at least the preceding 3 months. Approval for the study was obtained from the local Research Ethics Committee, and informed consent was obtained from all participants. Statistical analysis. Means or frequencies of potential confounding variables were calculated as appropriate. Unpaired Student's t tests or analyses of variance were conducted to assess statistical significance of differences between groups using Stat View software (version 5.0; SAS Institute, Cary, NC). Because plasma triglyceride concentration showed a skewed distribution, logarithmic (log) transformation was carried out before performing a correlation analysis. Correlations between serum bioavailable testosterone concentration and hemoglobin concentration or GA/HbA1c, as well as between GA/HbA1c and age, duration of diabetes, BMI, or other variables were examined by Pearson's correlation analyses. All continuous variables are presented as the mean±SD. Multiple linear regression analysis was performed to assess the combined influence of variables on hemoglobin concentration or GA/HbA1c. To examine the effects of various factors on hemoglobin concentration or GA/HbA1c, the following factors were considered as independent variables: serum bioavailable testosterone concentration, age, duration of diabetes, BMI, systolic blood pressure, plasma total cholesterol concentration, and smoking status. A P value <0.05 was considered statistically significant.
RESULTS
Characteristics of the 222 men with type 2 diabetes enrolled in this study are shown in Table 1 . The mean value of GA/HbA1c was 2.94±0.38.
Relationships between GA/HbA1c and other variables are shown in Table 2 . Age, duration of diabetes, and plasma HDLcholesterol concentration were positively associated with GA/HbA1c, while BMI, waist circumference, systolic blood pressure, diastolic blood pressure, plasma total cholesterol concentration, and log (plasma triglyceride concentration) were negatively associated with GA/HbA1c. A positive correlation was found between serum bioavailable testosterone and hemoglobin concentrations (r=0.368, P<0.0001; Fig. 1A ), while a negative correlation was found between serum bioavailable testosterone concentration and GA/HbA1c (r=-0.278, P<0.0001; Fig.  1B GA and HbA1c have a tendency to vary in parallel, although the normal range of variation of GA/HbA1c has not yet been determined. GA and HbA1c are equivalent measures of glycemic control in general, although the former is short term and the latter is long term marker. In certain diabetic patients in whom HbA1c measurement proves insufficient for clinical management (8, 9) , measurement of serum GA represents an alternative assessment of glycemic control. For example, anemia is an important factor affecting HbA1c levels. Thus, changes in the GA/HbA1c would indicate artefactual change, which make GA/HbA1c to have a clinical value.
Our results suggest that we may underestimate HbA1c level in male diabetic patients with hypogonadism because of a negative association between serum bioavailable testosterone concentration and GA/HbA1c that arises partly from a positive association between serum bioavailable testosterone and hemoglobin concentrations. Men with diabetes have significantly lower plasma concentrations of endogenous androgen than nondiabetic men (12-15); endogenous androgen concentrations also decline with advancing age (16) . Diabetic men with poor control or advanced age should be paid close attention to the evaluation of HbA1c levels.
GA/HbA1c was negatively associated with BMI or waist circumference in the present study. Koga et al. (17) made a similar observation, suggesting that increased serum albumin turnover in obese subjects could keep serum GA low relative to plasma glucose concentrations. We additionally found age to be positively associated with GA/HbA1c and systolic blood pressure or plasma total cholesterol concentration to be negatively associated with GA/HbA1c. Although the reasons for these associations are not clear, possible explanations may be that age (r=-0. Figure 1 . Correlations between serum bioavailable testosterone and hemoglobin concentrations (A), and between serum bioavailable testosterone concentration and the ratio of glycated albumin to glycated hemoglobin (GA/HbA1c)(B) in men with type 2 diabetes.
